Paule B, Saint F
Service d'Urologie, Hôpital Henri Mondor, 51, avenue du Maréchal de Lattre de Tassigny, 94010 Créteil.
Prog Urol. 2001 Feb;11(1):132-40.
The development of new treatment techniques, including concomitant chemotherapy/radiotherapy, appears to achieve higher response rates in advanced bladder cancer. Previous studies have suggested that continuous infusion chemotherapy and concomitant irradiation act synergistically to induce significantly increased tumour cell destruction. With the combination of 5FU and radiotherapy, the local control rate of transitional cell bladder cancers was 70% with a 5-year survival rate of 36% to 62%. Concomitant cisplatin and irradiation improved the control of locally advanced bladder cancers, but failed to improve overall survival. The use of concomitant cisplatin has no effect on distant metastases. These treatment modalities require further evaluation because of the relationships between radiotherapy- and drug-induced apoptosis, delayed cell death, survival of clonogenic cells, clinical response and overall survival. The optimum concomitant chemotherapy/radiotherapy protocol has not yet been defined.
包括同步放化疗在内的新治疗技术的发展,似乎能在晚期膀胱癌中取得更高的缓解率。既往研究表明,持续输注化疗和同步放疗具有协同作用,可显著增加肿瘤细胞破坏。5-氟尿嘧啶(5FU)与放疗联合应用时,移行细胞膀胱癌的局部控制率为70%,5年生存率为36%至62%。顺铂与放疗同步应用改善了局部晚期膀胱癌的控制,但未能提高总生存率。同步应用顺铂对远处转移无影响。由于放疗和药物诱导的细胞凋亡、延迟性细胞死亡、克隆源性细胞存活、临床反应和总生存率之间的关系,这些治疗方式需要进一步评估。最佳的同步放化疗方案尚未确定。